

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
ACTING AS THE DESIGNATED/ELECTED OFFICE

In re: Patent application of: Patrick Gerard JOHNSTON
Daniel LONGLEY

Application No: Not yet assigned
(International Application No: PCT/GB2004/005008)
Filed: (International Application: 26 November 2004 (26.11.2004))
For: COMBINATION THERAPY


Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

The present application is a 35 U.S.C. § 371 of PCT/GB2004/005008. Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, submitted herewith in duplicate as a substitute PTO Form 1449 listing the references cited in the Search Report in the international phase. A copy of the International Search Report is enclosed.

It is believed that copies of the references have been or will be forwarded by the International Search Authority. The Examiner is encouraged to contact the undersigned if reference copies have not been received.

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10	
EXPRESS MAIL Mailing Label Number:	EV545927646US
Date of Deposit:	May 26, 2006
I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, and/or fee, is being deposited with the United States Postal Service, "EXPRESS MAIL-POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
	
Signature of person mailing page:	
KAREN M. SPINA	
Type or print name of person	

INFORMATION DISCLOSURE STATEMENT
US NATL. PHASE OF PCT/GB2004/005008

ATTORNEY DOCKET NO. 36920-0416-00-US

The Examiner is respectfully requested to review the items listed on the substitute PTO Form 1449 and make them of record in the instant application as required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate substitute PTO Form 1449, and return one copy to the undersigned.

This Information Disclosure Statement should not be construed as a representation that the cited references are material or that more relevant prior art does not exist.

This Information Disclosure Statement is being submitted concurrently with the filing of the above-referenced application. Therefore, no certification, petition or fee is required. However, should a fee be due, authorization is hereby provided to charge Deposit Account No. 50-0573.

Respectfully submitted,

Gerard Patrick JOHNSTON et al.

BY 

DANIEL A. MONACO
Registration No. 30,480
DRINKER BIDDLE & REATH LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
TEL: (215) 988-3312
FAX: (215) 988-2757
Attorney for Applicants

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 36920-0416-00-US	SERIAL NO. Not Yet Assigned (I.A. PCT/GB2004/005008)
	APPLICANT: Gerard Patrick JOHNSTON et al.	
	FILING DATE Herewith (I.A. 26 November 2004)	GROUP Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	<u>TRANSLATION</u>	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/M.N./	AA	Allen et al., "Activation of Fas-mediated cell death in response to 5-fluorouacil and antifolate chemotherapies", <i>Proceedings of the American Research Annual Meeting</i> , 44: 418, 2003.
/M.N./	AB	Backu et al., "Thymidylate synthase inhibition triggers apoptosis via caspases-8 and 9 in both wild-type and mutant p53 colon cancer cell lines", <i>European Journal of Cancer</i> , 39(9): 1310-1317, 2003.
/M.N./	AC	Kim et al., "p53-independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, C1-IB-MECA", <i>Biochemical Pharmacology</i> , 63(5): 871-880, 2002.

EXAMINER /Meera Natarajan/	DATE CONSIDERED 07/16/2008
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

SUBSTITUTE FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
36920-0416-00-USSERIAL NO.
Not Yet Assigned
(I.A. PCT/GB2004/005008)

INFORMATION DISCLOSURE STATEMENT

APPLICANT:
Gerard Patrick JOHNSTON et
al.FILING DATE
Herewith
(I.A. 26 November 2004)GROUP
Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/M.N./	AA	Allen et al., "Activation of Fas-mediated cell death in response to 5-fluorouacil and antifolate chemotherapies", <i>Proceedings of the American Research Annual Meeting</i> , 44: 418, 2003.
/M.N./	AB	Backu et al., "Thymidylate synthase inhibition triggers apoptosis via caspases-8 and 9 in both wild-type and mutant p53 colon cancer cell lines", <i>European Journal of Cancer</i> , 39(9): 1310-1317, 2003.
/M.N./	AC	Kim et al., "p53-independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, C1-IB-MECA", <i>Biochemical Pharmacology</i> , 63(5): 871-880, 2002.

EXAMINER /Meera Natarajan/

DATE CONSIDERED 07/16/2008

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.